Opus Genetics Files 8-K on Officer/Director Changes

Ticker: IRD · Form: 8-K · Filed: Sep 2, 2025 · CIK: 1228627

Sentiment: neutral

Topics: leadership-change, corporate-governance, filing

TL;DR

Opus Genetics 8-K: Leadership changes and financial updates filed Aug 29.

AI Summary

Opus Genetics, Inc. filed an 8-K on August 29, 2025, reporting on the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements. The filing also includes Regulation FD disclosures and financial statements/exhibits. The company was formerly known as Ocuphire Pharma, Inc., REXAHN PHARMACEUTICALS, INC., and CORPORATE ROAD SHOW DOT COM INC.

Why It Matters

This filing indicates potential shifts in the company's leadership and governance structure, which could impact strategic direction and operational execution.

Risk Assessment

Risk Level: medium — Changes in directors or officers can signal internal shifts that may affect company strategy or stability.

Key Players & Entities

FAQ

What specific changes were made regarding directors or officers?

The filing indicates reporting on the departure of directors or certain officers, election of directors, and appointment of certain officers, but the specific names and details are not provided in this excerpt.

What is the primary purpose of this 8-K filing?

The primary purpose is to report current events, including changes in the company's leadership, compensatory arrangements, and to include Regulation FD disclosures and financial statements/exhibits.

When was the earliest event reported in this filing?

The earliest event reported in this filing occurred on August 29, 2025.

What were Opus Genetics, Inc.'s previous names?

Opus Genetics, Inc. was formerly known as Ocuphire Pharma, Inc., REXAHN PHARMACEUTICALS, INC., and CORPORATE ROAD SHOW DOT COM INC.

What is the company's principal executive office address?

The company's principal executive office is located at 8 Davis Drive, Suite 220, Durham, NC 27713.

Filing Stats: 1,048 words · 4 min read · ~3 pages · Grade level 9.9 · Accepted 2025-09-02 16:52:07

Key Financial Figures

Filing Documents

02

Item 5.02 Departure of Directors or Certain Officers Election of Directors Appointment of Certain Officers Compensatory Arrangements of Certain Officers. On August 29, 2025, Opus Genetics, Inc., a Delaware corporation (the " Company "), appointed Robert Gagnon as the Company's Chief Financial Officer and principal accounting officer, effective September 2, 2025 (the " Effective Date "). In connection with his appointment, on August 29, 2025, Mr. Gagnon entered into an employment agreement (the " Employment Agreement "), effective as of the Effective Date, setting forth the terms of his employment with the Company. Pursuant to the Employment Agreement, for his service as Chief Financial Officer, Mr. Gagnon will receive an annual base salary of $465,000 and will be eligible to earn an annual performance bonus of up to 45% of his annual base salary for the applicable bonus year. The Company will issue Mr. Gagnon a stock option to purchase 250,000 shares of the Company's common stock and an award for 200,000 shares of the Company's common stock pursuant to the Company's 2021 Inducement Plan, in each case subject to vesting over a period of four years. Mr. Gagnon is also eligible to participate in other benefits available to employees of the Company, including the Company's paid vacation and sick leave plans, welfare and benefit plans, disability plans, and medical, death benefit, and life insurance plans. There is no arrangement or understanding between Mr. Gagnon and any other person pursuant to which Mr. Gagnon was selected as the Company's Chief Financial Officer. Mr. Gagnon has no family relationships with any director, executive officer, or person nominated or chosen by the Company to become a director or executive officer of the Company. Mr. Gagnon is not a party to any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K. The foregoing summary of the Employment Agreement is qualified by reference to the complete text of the Employ

01

Item 7.01 Regulation FD Disclosure. A copy of the press release announcing Mr. Gagnon's appointment is attached hereto as Exhibit 99.1. The information in this Item 7.01 of this Current Report on Form 8-K, and Exhibit 99.1, is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such a filing.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1* Employment Agreement, dated as of August 29, 2025, by and between the Company and Robert Gagnon. 99.1 Press Release, dated September 2, 2025. 104 Cover Page Interactive Data File (embedded within Inline XBRL document). * Indicates management contract or compensatory plan. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: September 2, 2025 OPUS GENETICS, INC. By: /s/ Dr. George Magrath Name: Dr. George Magrath Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing